These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Acute abdomen due to massive abdominal wall hematoma]. Varona JF; Díaz-Corandi R; Valle M; Muñoz F; Bufalá MA Rev Esp Enferm Dig; 2007 Feb; 99(2):120-1. PubMed ID: 17417929 [No Abstract] [Full Text] [Related]
10. [Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report]. Ohya E; Mizutani M; Sekine T Nihon Naika Gakkai Zasshi; 2012 Jan; 101(1):168-71. PubMed ID: 22413476 [No Abstract] [Full Text] [Related]
11. Diffuse alveolar hemorrhage associated with lenalidomide. Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890 [No Abstract] [Full Text] [Related]
12. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide. Iino M Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829 [No Abstract] [Full Text] [Related]
13. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. Walavalkar V; Adey DB; Laszik ZG; Jen KY Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456 [TBL] [Abstract][Full Text] [Related]
14. Neutrophilic dermatosis complicating lenalidomide therapy. Thieu KP; Rosenbach M; Xu X; Kist JM J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007 [TBL] [Abstract][Full Text] [Related]
16. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. Dasanu CA; Alexandrescu DT Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868 [TBL] [Abstract][Full Text] [Related]
17. Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. Wedel W; Sofronescu AG Am J Clin Pathol; 2015 Aug; 144(2):329-32. PubMed ID: 26185319 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096 [TBL] [Abstract][Full Text] [Related]
19. Myeloma and second primary cancers. Landgren O; Thomas A; Mailankody S N Engl J Med; 2011 Dec; 365(23):2241-2. PubMed ID: 22150057 [No Abstract] [Full Text] [Related]
20. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147 [No Abstract] [Full Text] [Related] [Next] [New Search]